Anthem Biosciences Q4 FY26 earnings call
In brief
Anthem posts highest-ever Q4 revenue ₹611 cr (+26% YoY); FY26 EBITDA ₹990 cr and PAT ₹592 cr each grew 30%+
- Management's tone
- Confident
- What was said
- Leaned positive
- Guidance
- None given
- Analyst pushback
- Low
- Stock, next session
- −0.87% (Nifty 50 +0.17%)
- Q4 FY26 was Anthem's highest-ever revenue quarter at ₹611 cr, up 26% YoY, with EBITDA at ₹318 cr and PAT at ₹190 cr.
- FY26 consolidated revenue from operations was ₹2,124 cr; CRDMO contributed 83% (₹1,773 cr, +18%) and Specialty Ingredients 17% (₹352 cr).
- FY26 EBITDA was ₹990 cr (margin 43.4%, up 420 bps) and PAT ₹592 cr (+31%); FY26 total revenue of ₹2,280 cr grew 18%.
- Net cash position stood at ₹1,375 cr as of March 31, 2026, supporting both organic and inorganic growth options.
- Unit 4 Phase 1 capex of ~₹1,200 cr planned over FY27-FY28 (₹700 cr FY27, ₹500 cr FY28) to add 365 KL custom synthesis and 100 KL fermentation capacity.
An AI read of the company's transcript · the filing
The numbers
The quarter, Q4 FY26
| This quarter | A year ago | Last quarter | Margin | |
|---|---|---|---|---|
| Revenue | ₹611 cr | — | +44.4% | |
| EBITDA (excl. other income) | ₹268 cr | — | +103.4% | 43.9% |
| Net profit | ₹190 cr | — | — | 31.1% |
| EPS (₹) | ₹0.00 | — | — |
From the company's filed results for the quarter ended 31 Mar 2026 (consolidated), not from the call. EBITDA here excludes other income, so it can differ from the figure management quotes.
Where management's figures differ from the filing
- EBITDA Q4 FY26: said EBITDA including other income ₹318 crores, margin 48.1%; filed EBITDA excl other income ₹268.19 cr, margin 43.9%. Management includes other income (₹51.21 cr) in EBITDA; filed excludes it. Reconciling: ₹318 cr − ₹51.21 cr ≈ ₹266.8 cr, near filed ₹268.19 cr.
What moved the numbers, as management explained it
- Backward integration of an intermediate completed during FY26, lifting material margins; gross margins sustained above 65% in Q3 and Q4.
- Restocking replacing destocking in CRDMO; management said destocking impact is largely behind them and revenue will be in positive territory.
- Four molecules transitioned from Phase 3 to commercial in FY26, contributing ~8-9% of revenue from new launches; peak sales 4-5 years from launch.
- Q4 EBITDA includes other income of ~₹51 cr (FY26 other income of ₹156 cr includes ₹63 cr forex/RoDTEP and ₹92 cr financial/non-operating), inflating the margin figure. (accounting)
- New Labor Code reassessment recognized a Rs. 98 lakhs credit as exceptional items in Q4 FY26. (one-off)
The numbers management led with
- EBITDA: Rs. 990 crores (43.4% margins), 31% YoY growth
- PAT: Rs. 592 crores (26% margins), 31% YoY growth
- Net cash position: Rs. 1,375 crores as of March 31, 2026
- Unit 4 Phase 1 capex: Rs. 1,200 crore over FY27-FY28; FY27 ~Rs. 700 crores, FY28 ~Rs. 500 crores
Guidance
Guidance on this call
| What | For | What management said |
|---|---|---|
| Unit 4 Phase 1 capex | FY27-FY28 | Invest almost about Rs. 1,200 odd crores across two years, this year FY27 and in FY28 for Unit 4 Phase 1. |
| FY27 capex | FY27 | Roughly about Rs. 700 crores capex in FY27. |
| FY28 capex | FY28 | About Rs. 500 crores capex in FY28. |
| Unit 4 Phase 1 capacity addition | FY28 | This will add close to about 365 kiloliters of custom synthesis capacity and 100 kiloliters of fermentation. |
| Specialty Ingredients growth aspiration | — | Overall, a 20% growth for specialty ingredients as well. |
| EBITDA margin | — | On analyst's 38-40% EBITDA margin assumption: We've delivered so far, and we'll continue to deliver those numbers going forward as well. |
| Long-term growth aspiration | — | Historically, we've grown upwards of 20% and we feel confident that this is what we want to maintain. |
Guided on earlier calls, and what was filed
| What | For | Guided | Filed |
|---|---|---|---|
| EBITDA margin | FY26 | at least 38% (on the Q1 FY26 call) | 38.1%, within the range |
| EBITDA margin (normalized, excl FX) | FY26 | 36–37% (on the Q2 FY26 call) | 38.1%, above the range |
Filed figures are summed from the company's own quarterly results for the whole period (EBITDA excludes other income); where one sits against what was guided is arithmetic, not a judgement.
The business
By business
CRDMO
CRDMO delivered Q4 revenue of ₹513 cr (+31% YoY) and FY26 revenue of ₹1,773 cr (+18%), 83% of FY26 revenue. Four molecules went commercial in FY26; commercial pipeline at 14, Phase 3 at 10, 100+ early-stage programs; new launches contribute ~8-9% of revenue.
Q4 FY26 revenue ₹513 cr, +31% YoY · FY26 revenue ₹1,773 cr, +18% YoY · 83% of FY26 revenue · 10 Phase 3 molecules · 14 commercial molecules · 100+ early-stage programs
Outlook: Aspires to 20%+ growth historically; capacity not a constraint after Unit 2 expansion and Unit 3 commissioning; ramp-up of new commercial molecules expected over 2-3 years to peak sales.
Specialty Ingredients
Specialty Ingredients delivered Q4 revenue of ₹98 cr (+8% YoY) and FY26 revenue of ₹352 cr (17% of FY26). First three quarters were flat, with growth returning in Q4.
Q4 FY26 revenue ₹98 cr, +8% YoY · FY26 revenue ₹352 cr · 17% of FY26 revenue
Outlook: Aspires to ~20% growth; dedicated facility in Unit 4 to address capacity cannibalisation by CRDMO.
Balance sheet, capex and funding
- Net cash position of ₹1,375 cr as of March 31, 2026.
- Unit 4 Phase 1 capex of ~₹1,200 cr spread over FY27 (~₹700 cr) and FY28 (~₹500 cr).
- Unit 2 expanded from 246 KL to 376 KL (50% addition); Unit 3 commissioned and operational.
- Cash flexibility supports potential inorganic acquisitions; no specific targets announced.
The industry, as management sees it
Biotech funding recovering strongly (~50% YoY growth). CRDMO in India gaining acceptance with big pharma and emerging biotech. GLP-1 opportunity substantial given diabetes/obesity market. Peptides currently largest commercial modality; ADC and oligonucleotides growing. India no longer faces mental barriers for giving work — positioned similarly to NCEs 20-25 years ago. AI emerging as discovery aid and manufacturing optimization tool.
Risks management named
- Tariff uncertainty in US market — managed via customer separate arrangements
- Biotech funding volatility — recovering but still monitored
- Capacity fungibility between CRDMO and specialty ingredients — addressed by dedicated Unit 4 facility
- AI disruption risk in discovery stage — monitored case-by-case
Q&A
Call dominated by questions on growth trajectory, capacity expansion plans (Unit 4), and competitive positioning. Analysts showed strong interest in GLP-1 opportunity, Phase 3 pipeline composition, and biotech funding recovery. No major pushback on strategy — management's technology-first approach and customer stickiness were well-received. US tariff concerns dismissed as immaterial given big pharma separate arrangements. Destocking narrative resolved positively. Phase 3 pipeline entirely from emerging biotech (not lateral entries) viewed favorably.
Not answered directly
- ADC payload specifics — confidential client work, not disclosed
Asked for a number, answered without one
- GLP-1 opportunity size and 2-3 year growth rate: Management declined forward-looking guidance; said they aspire to growth historically delivered (20%+) and are positioned to replace Chinese-sourced APIs but did not quantify opportunity size or growth.
- ADC payload types and names: MD said not at liberty to disclose; noted 15-20 payloads worked on, some proprietary to clients.
- Big pharma vs biotech split for 10 Phase 3 molecules: CFO said additions were non-lateral, all from emerging biotech funnel; described modality mix (ADC, peptides, oligos) but did not give big pharma vs biotech split for the 10.
Every question, with its answer
1. CRDMO growth trajectory & destocking
Bansi Desai, JP Morgan
Question. How should we think about CRDMO growth for research and manufacturing in FY27? Are the destocking impacts on key products largely resolved?
Answer, Ajay Bhardwaj, MD & CEO. Aspires to deliver ~20% growth as historically achieved. Destocking occurred with many customers but strong growth delivered despite it. Expect destocking to swing to restocking, positively impacting top and bottom line — mostly behind us now.
Follow-up. How do we intend to augment relationships with more innovators? With capacity coming online in two years, should we see broadening with more big pharma?
Answer. Two notable big pharma additions last year through direct contacts; relationships growing healthily. Customers build confidence gradually before giving larger contracts. Phase 3 pipeline of 10 molecules in small biotechs, historically acquired by big pharma, will bring new relationships. 100+ R&D projects position us well to add more big pharma customers.
2. Strategic gaps and M&A strategy
Saion Mukherjee, Nomura Holdings
Question. What are the missing pieces to become more agile and future-ready CRDMO platform — organically or inorganically (India or abroad)?
Answer, Ajay Bhardwaj, MD & CEO. Investing heavily in technology: continuous manufacturing, better automation and control, green chemistry at commercial scale. Early-stage programs allow implementing new technologies before regulatory filings, earning customer and regulator respect. On acquisitions, actively scouting but will not do acquisition for the sake of it — must be the right asset.
Follow-up. What is the capex number for FY27 and medium-term capex outlook over 3-4 years?
Answer. Unit 4 is the major capex — Phase 1 investment ~Rs. 1,200 crore across FY27 and FY28, completing towards latter half of March 2028. This adds 365 kiloliters custom synthesis capacity and 100 kiloliters fermentation (current: 425 kiloliters custom synthesis + 180 kiloliters fermentation — roughly doubling custom synthesis, adding 50% fermentation). FY27 capex ~Rs. 700 crores, followed by ~Rs. 500 crores. Unit 4 is larger than all Units 1-3 combined on 30 acres. Two more phases planned post-March 2028, potentially tripling overall capacity.
3. New order modalities
Debanjan Bhakta, Universal Sompo General Insurance
Question. What modalities are new RFQ orders coming in — biological or chemical entities?
Answer, Gawir Baig, CFO. Orders coming in across both custom synthesis and biology sides, including advanced technologies like peptides and RNAi.
Follow-up. What payload is being developed in the ADC platform?
Answer. Cannot disclose — confidential work for clients. Anthem works on 15-20 payloads, some proprietary, making it a very interesting area with huge activity.
Not answered directly.
4. Destocking, GLP-1 opportunity, differentiators
Vivek Gautam, GS Investment
Question. Any destocking risk? What is the GLP-1 opportunity size and expected growth rate for next 2-3 years? What differentiates Anthem?
Answer, Ajay Bhardwaj, MD & CEO. Destocking already happened — restocking underway, everything positive this year. On GLP-1, in conversations with all big players to give India-based alternative to China-sourced active. Very well-positioned for GLP-1, will benefit after major launches. Aspires to maintain historical 20%+ growth rate but does not give forward guidance. Differentiators: focus on small biotechs and discovery vs FTE-based business; unmatched technology in India; 40% of employees on ESOP creating young, energized workforce reflected in margins.
Follow-up. Any risk from AI in discovery stage?
Answer. AI coming into all functions — HR, warehousing, etc. Picking use cases and implementing case-by-case. Not an overarching switch. Work-in-progress, constantly exploring.
5. Peptide competition and differentiation
Vivek Rakholiya, Ficom Family Office
Question. A listed peer claims full peptide chain capability from fragments to APIs and is expanding capacity. How does Anthem differentiate against domestic and international competition?
Answer, Ajay Bhardwaj. Peptides are diverse — different strategies for different peptides (convergent synthesis, serial step-by-step, biosynthesis). Anthem works on 10-12 peptides, each following optimal economic strategy for best cost of goods. Not privy to competitor claims but Anthem has extremely competitive cost of goods in GLP-1 peptides, rivaling Chinese players. In very good place.
Follow-up. Is peptide TAM larger than oligonucleotides? How would you rank capability and TAM across peptides, oligonucleotides, and ADCs?
Answer. Peptides are currently the most commercially successful with largest TAM given diabetes and obesity. ADCs are very big growth area when peptides don't work. Oligonucleotides are also prevalent. Anthem has capability across all three modalities — all are new modalities where Anthem's technology-driven approach excels. All do specific jobs designed for; Anthem present in all strongly. Peptides largest near-term given huge diabetes/obesity market.
6. Large molecule strategy and competitive positioning
Dhawal Khut, Jefferies
Question. What steps are being taken to build large molecule pipeline? How willing are innovators to give projects to Indian CRDMO? Does India have cost advantage vs Korea/China in large molecules?
Answer, Ajay Bhardwaj, MD & CEO. Anthem equally focused on biology and chemistry. Working with 4-5 projects as development and hopefully manufacturing partner in large molecules. No resistance to India — any issues lie in capacity, not willingness. Korean and Chinese large companies have built massive capacities and are ahead. Strategy: excel in early development so clients don't want to transfer regulatory work. Cannot compete with Celltrion, Samsung, or Lonza for ready-made projects, but Indian companies in similar position to NCEs 20-25 years ago. Mental barriers to giving work to India have dissolved.
Follow-up. What is the biosimilar asset progress and when will it hit P&L? Will it be under CRDMO or specialty ingredients?
Answer. Going really well — refiling three batches underway. Approval lead time for another site typically one year; should hit P&L next year. Will be classified under CRDMO.
7. Specialty ingredients business and growth
Ashish, UTI
Question. What is the specialty ingredients order book? Is this segment a victim of destocking as revenue growth shows?
Answer, Gawir Baig, CFO. Specialty ingredients includes serratiopeptidase, vitamins, probiotics, enzymes for India and RoW markets. Different from CDMO — own products sold to multiple customers. First three quarters flat but Q4 saw 8% growth. Aspiring for 20% growth similar to CDMO business. No order book concept — flow business manufacturing and selling across multiple geographies and product categories.
Follow-up. With fungible gross block, how do you maintain margins? Is 38-40% EBITDA margin a fair assumption?
Answer. Aspiration same across revenue, EBITDA, PAT. Costs escalate in similar growth rate as business; operating leverage maintains margins. Delivered 38-40% and will continue to deliver those numbers going forward.
8. Long-term vision and margin sustainability
Saion Mukherjee, Nomura Holdings
Question. Anthem is still small vs global peers. Even at 20% growth, scale will double or triple in 4-5 years. Are you at an inflection point where CRDMO in India and Anthem are gaining traction faster? Can profitability at these levels be sustained given execution challenges?
Answer, Ajay Bhardwaj, MD & CEO. Envisioned 5-7 years of growth. Unit 4 capacity will exceed all current units combined when filled. Growing faster than most peers despite smaller size. Investing for future — wouldn't invest this much if not looking 5 years ahead. Keen on acquisitions with right quality and geography; cash position allows flexibility. Margins are very high; maintaining them is a yeoman task but believe can not only maintain but grow them. Better than peers in growth and margins, intend to stay there.
9. CRO performance and gross margin drivers
Amey Chalke, JM Financial Institutional Securities
Question. How did CRO perform during the year and quarter? GM has gone above 65% consistently — is this from higher CRO mix and what is the outlook?
Answer, Gawir Baig, CFO. GM improvement from backward integration for one intermediate — now source raw material, manufacture intermediates and API, not reliant on external source. Integration complete, showing in Q3 and Q4 margins. Revenue breakdown: commercial ~60%, development and manufacturing batches ~15%, R&D ~8-9%, specialty ingredients ~17%. 4 molecules commercialized last year; commercial pipeline now 14. Late-stage pipeline 10 Phase 3 molecules; 100+ early-stage programs.
Follow-up. How do you see AI evolution in CRDMO space — any material advantage for manufacturing side?
Answer. AI will be big aid in discovery (molecule identification given target) and route optimization for manufacturing. Manufacturing still needs to be done — 83% of business protected. AI will optimize plants and improve margins. Implementing case-by-case where maximum benefit seen.
10. GLP-1 commercialization timeline
Amey Chalke, JM Financial Institutional Securities
Question. On GLP-1, when is commercialization expected on generic side and can it be material?
Answer, Ajay Bhardwaj, MD & CEO. Will be big contributor going forward, pretty sure of it. Customers working on new formulations with Anthem material — timeline depends on their approval timelines. Could happen in 6-8 months, positioned well.
Partly answered.
11. Phase 3 pipeline composition
Dhawal Khut, Jefferies
Question. How many of the 4 recently added Phase 3 molecules are lateral entry vs graduating from Phase 2? What is the big pharma vs biotech split and modalities of the 10-molecule basket?
Answer, Gawir Baig, CFO. All 4 Phase 3 additions are non-lateral — worked from early Phase 2 and moved to Phase 3. All from emerging biotech funnel (work from discovery through development to supply quantities as programs progress). Good mix across ADC, biotransformation molecules, peptides, oligos — not dominated by one therapeutic or technology category. All 10 molecules from emerging biotech.
Follow-up. Is US pharma tariff creating BD challenges with US customers?
Answer. No impact. Commercial products with big pharma have separate tariff arrangements with administration. Early-stage biotech still in drug candidate category — no impact so far. Biotech taking tariff situation with equanimity given undefined intent and back-and-forth. India and America seen as on same side.
12. Biotech funding environment
Udit Bokaria, Catamaran
Question. When do we expect the 4 molecules from acquired biotech to be commercially launched by big pharma? What are US biotech partners saying about funding environment and are inquiries increasing?
Answer, Gawir Baig, CFO. Biotech funding recovering — up ~50% YoY through April. Seeing increase in early-stage development project requests. Projects smaller in size but number of requests increasing. Biotech funding not a concern.
Follow-up. When can we expect ramp-up for the 4 commercial molecules launched last year?
Answer. Peak sales estimates for 4 commercial molecules are 4-5 years from launch. Two to three years for ramp-up as customers launch in one geography, file registrations, and launch in others. Current contribution from these 4 molecules ~8-9% of revenues. Ramp-up will take time.
13. Project capacity and scaling
Udit Bokaria, Catamaran
Question. Currently doing 100 projects — what is peak capacity for inquiries and how are we ramping up?
Answer, Ajay Bhardwaj, MD & CEO. Unit 3 with many labs built to handle more projects. Projects come in different slices — some at early chemistry development, some at optimization, some at commercial optimization. Different teams address different stages. Can handle many more projects. If projects go to 200, will be fine.
What was said
Topic by topic, in the order it was spoken
FY26 Full Year Financial Performance · Ajay Bhardwaj (MD & CEO)
- Consolidated revenue from operations Rs. 2,124 crores; CRDMO contributed 83% (Rs. 1,773 crores, 18% growth YoY); Specialty ingredients 17% (Rs. 352 crores)
- Total revenue Rs. 2,280 crores including other income (Rs. 156 crores); growth of 18% YoY
- EBITDA Rs. 990 crores (43.4% margins), 31% growth in absolute terms, 420bps margin expansion
- PAT Rs. 592 crores (26% margins), 31% growth YoY; net cash position Rs. 1,375 crores
Q4 FY26 Quarterly Performance · Ajay Bhardwaj (MD & CEO)
- Q4 FY26 highest-ever revenue quarter: Rs. 611 crores, 26% YoY growth
- CRDMO Rs. 513 crores (31% YoY), Specialty ingredients Rs. 98 crores (8% YoY)
- EBITDA Rs. 318 crores (48.1% margins), 52% growth YoY; PAT Rs. 190 crores (28.7% margins), 130% growth YoY
- New Labor Code implementation resulted in Rs. 98 lakh exceptional credit
FY27 Strategic Priorities · Ajay Bhardwaj (MD & CEO)
- Build one of the most agile, science-led, and future-ready CRDMO platforms globally
- Commitment to prudent cost management and long-term value creation
- Sustainable growth across all business segments
- Focus on technology platforms differentiating from peers
Closing Remarks and Growth Aspirations · Ajay Bhardwaj (MD & CEO)
- Aspiration to be most admired, agile CRDMO with best global practices
- Customer trust demonstrated by long-term relationships and stickiness
- Unit 3 already turning around, expected positive in FY27; Unit 4 ready next financial year
- Confident about future investments and becoming leading CRDMO from India
In their words
We are very different from our peers in India. We are more focused on small biotech's, and therefore, we are more on the discovery side rather than the full-time equivalent type of business. What we differentiate ourselves is by technology as well. I think in that we have no peers in the country.
Unit 4 is going to be much larger than all the units put together. So, it's a 30 acre piece of land, and all our Units 1, 2, and 3 put together is close to about 30 acres. In Phase 1 of that expansion, we are looking at investing almost about Rs. 1,200 odd crores across two years.
I think we're in a good place. More than 100 projects we're doing in R&D are in early stages, and 10 of them are in Phase 3. We are in a good place to add more big pharma customers to our portfolio.
To check next time
What management committed to on this call, or the dates they gave.
- Unit 4 Phase 1 construction progress; targeted completion March 2028, with ~₹700 cr capex spend in FY27.
- Specialty Ingredients 20% growth aspiration, supported by dedicated Unit 4 facility.
- GLP-1 commercialisation timing — management indicated 6-8 months for India generic launches.
- Ramp-up of four molecules that went commercial in FY26; peak sales 4-5 years from launch.
- Biotech funding trajectory — management noted ~50% YoY recovery through April 2026.
- Biosimilar asset P&L contribution, expected in CRDMO from FY27 with site approval cycle of ~1 year.
Transcript
We have not transcribed this call's recording. Read the company's transcript (PDF).
The stock after the call
| After the call | Close | Stock | Nifty 50 |
|---|---|---|---|
| Next session Wed 20 May 2026 | ₹780.50 | −0.87% | +0.17% |
| 5 sessions Tue 26 May 2026 | ₹772.25 | −1.92% | +1.25% |
| 20 sessions Wed 17 Jun 2026 | ₹767.50 | −2.52% | +1.98% |
From the close of Tue 19 May 2026, ₹787.35: the close before the call day (the call's time is not on file). Adjusted daily closes; the move includes everything else that happened in those sessions.